ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial.
about
Cholesterol crystals and inflammationNLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystalsCarotid intima-media thickness studies: study design and data analysis.Modulation of triglyceride and cholesterol ester synthesis impairs assembly of infectious hepatitis C virus.Membrane plasmalogen composition and cellular cholesterol regulation: a structure activity study.Identification of modules related to programmed cell death in CHD based on EHENCarotid intima-media thickness in individuals with and without type 2 diabetes: a reproducibility study.HPLC-FLD determination of NBD-cholesterol, its ester and other metabolites in cellular lipid extracts.Inflammasome activation in obesity-related inflammatory diseases and autoimmunity.Multimodal cardiovascular magnetic resonance quantifies regional variation in vascular structure and function in patients with coronary artery disease: relationships with coronary disease severity.Sex-specific association of ACAT-1 rs1044925 SNP and serum lipid levels in the hypercholesterolemic subjectsBeneficial clinical effects of grape seed proanthocyanidin extract on the progression of carotid atherosclerotic plaques.Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial.Macrophages, dendritic cells, and regression of atherosclerosis.Carotid Intima-media Thickness Measurements: Relations with Atherosclerosis, Risk of Cardiovascular Disease and Application in Randomized Controlled TrialsRole of HDL in cholesteryl ester metabolism of lipopolysaccharide-activated P388D1 macrophagesAssociation between single nucleotide polymorphism rs1044925 and the risk of coronary artery disease and ischemic stroke.Assessing individual cardiac risk using extra-cardiac arterial imaging.Isoform-specific inhibitors of ACATs: recent advances and promising developments.New lipid-lowering drugs: an update.New treatments on the horizon for familial hypercholesterolemia.Carotid intima-media thickness testing as an asymptomatic cardiovascular disease identifier and method for making therapeutic decisions.An overview of the new frontiers in the treatment of atherogenic dyslipidemias.Emerging drugs for hyperlipidaemia: an update.Acyltransferase inhibitors: a patent review (2010-present).Cholesterol crystal induced arterial inflammation and destabilization of atherosclerotic plaque.Apolipoprotein A-I Helsinki promotes intracellular acyl-CoA cholesterol acyltransferase (ACAT) protein accumulation.Identification of potential ACAT-2 selective inhibitors using pharmacophore, SVM and SVR from Chinese herbs.Inefficacy interim monitoring procedures in randomized clinical trials: the need to report.7-Chlorofolipastatin, an inhibitor of sterol O-acyltransferase, produced by marine-derived Aspergillus ungui NKH-007.Time-related trends in variability of cIMT changes in statin trialsUsing self-organizing map (SOM) and support vector machine (SVM) for classification of selectivity of ACAT inhibitors.In vitro metabolism of pyripyropene A and ACAT inhibitory activity of its metabolites.Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications.Acute Coronary Syndromes: The Way Forward From Mechanisms to Precision Treatment.ATR-101 inhibits cholesterol efflux and cortisol secretion by ATP-binding cassette transporters, causing cytotoxic cholesterol accumulation in adrenocortical carcinoma cells.Increasing spatial resolution of 3T MRI scanning improves reproducibility of carotid arterial wall dimension measurements.New verticilides, inhibitors of acyl-CoA:cholesterol acyltransferase, produced by Verticillium sp. FKI-2679.Quantitative Trait Locus Mapping of Macrophage Cholesterol Metabolism and CRISPR/Cas9 Editing Implicate an ACAT1 Truncation as a Causal Modifier Variant.Clinical and genetic factors influencing cardiovascular risk in patients with familial hypercholesterolemia
P2860
Q27024737-23655B08-B947-4F2A-AF8C-BA82407EC104Q29615704-1DAFE966-B8DF-4250-872F-E3DD4BAE79A9Q30712446-A11491B6-8DB2-46AB-8BCE-A3F9D02A1989Q33985223-CB8B6C82-9CB6-40E9-B4E5-B900A3CB2B28Q33986680-6F3959E3-3B34-42BE-AE90-770D6E06B82BQ34009719-448699D4-DEB6-403F-8414-17E19D7B4711Q34097974-5133D6C2-FB36-42CB-A281-1A1906A84D46Q34633759-BA60AD67-32CE-4ADC-8D22-FEFAE6EB6672Q34701729-0A45476D-0090-4710-B726-74FF84E84865Q35666715-2732F3D4-5B08-499F-8312-4B2B7B2473DBQ35735737-F07F85E8-EF58-482F-A4C2-753649782278Q36011294-B4DA7CF6-2BBC-4D74-B414-5395B1E9061AQ36124203-A7C14EC8-A8FE-4952-B5A0-E4AD020B8C0DQ36193752-2EA0B2D8-5147-45A1-86F3-2D4D572DF57FQ36705497-C2E02D11-1353-4BA5-9A71-E0A4425638ECQ37222713-EC0EE4BE-9F1F-4722-A2BC-98DD702F6178Q37683973-FBCD1031-B80B-43E7-9646-9E62DD4BFD78Q37732244-A7238E3A-6FF7-44B9-8709-1885E5572AECQ37958067-2ACCAE1C-1451-4891-9638-0B39F4F0097FQ37984782-9E709E08-447C-4874-8038-955AB087DA33Q38063288-7C5EEFE6-4C6D-4C3A-8993-D4FEF13CFED1Q38118481-B973AADB-DE7E-45DC-B675-30B974A6C461Q38204183-876EB1DC-0BAF-474F-A5CF-5F890D38F7E9Q38263909-EE98C7B7-5656-4FB0-B8E0-DA63AF3E7499Q38282398-6CE35578-064C-4271-999B-1A4CCBD7250BQ38679802-2E5CCC9A-ECA9-4369-ADD0-7E4305C69ADBQ39186016-C4E41369-B851-4FE7-B627-AF03EBF94088Q39666046-CFF59E9D-4882-4A5B-AC65-FBBEEE78C321Q39772400-EEE28E0C-409E-4EC2-AE66-636508590F0FQ39917867-AE78B1D4-F18A-468D-9074-84A69F90A202Q39976994-E262F45B-C577-4EBF-B4C6-2733B65C3523Q44976261-E7E42676-81F0-4290-92EC-D174F2799340Q46188706-B2D41C49-7B25-4C7E-9476-1E0800CC3BE5Q47566445-4E98E76A-5456-4D5A-9A87-7C245C7AA838Q47782268-D9B72582-043D-49E9-9991-F6CC29AEA4F3Q48121227-3AA8EC2E-66E2-45E3-93DD-3DA009CD4492Q51163101-E4884E96-A205-4421-A19C-D5F264700A45Q51760389-DDCAC3E0-A019-4330-A55D-DB05B823D072Q52429266-0BD9BB09-1889-46DE-B41D-298237EB1F5DQ57364764-545CA2EB-D7C1-4EBE-BD4F-D26D7ADB69D9
P2860
ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
ACAT inhibition and progressio ...... he CAPTIVATE randomized trial.
@en
type
label
ACAT inhibition and progressio ...... he CAPTIVATE randomized trial.
@en
prefLabel
ACAT inhibition and progressio ...... he CAPTIVATE randomized trial.
@en
P2093
P356
P1476
ACAT inhibition and progressio ...... the CAPTIVATE randomized trial
@en
P2093
Aeilko H Zwinderman
CAPTIVATE Investigators
Dick C G Basart
Eric de Groot
Evan A Stein
Frans J Maritz
John J P Kastelein
Lee R Schwocho
Marijn C Meuwese
P304
P356
10.1001/JAMA.301.11.1131
P407
P577
2009-03-01T00:00:00Z